^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LILRB4 overexpression

    i
    Other names: LILRB4, Leukocyte Immunoglobulin Like Receptor B4, LIR-5, ILT3, LIR5, Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 4, Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4, Leukocyte Immunoglobulin-Like Receptor 5, CD85 Antigen-Like Family Member K, Monocyte Inhibitory Receptor HM18, Immunoglobulin-Like Transcript 3, Leucocyte Ig-Like Receptor B4, CD85k, ILT-3, HM18, B4, CD85k Antigen, CD85K
    Entrez ID:
    11006
    1year
    Chimeric Antigen Receptor T Cells Targeting LILRB4, an Immunoreceptor Mediating T-Cell Suppression, Are Potently Effective in Multiple Myeloma (ASH 2023)
    Equal efficacy is observed in U266 cells resistant to Bortezomib and BCMA KO U266 cells...Our work supports the rationale development of ILT3 CAR-T cell therapy as a viable therapeutic approach for MM patients especially high-risk patients. Ongoing studies are investigating the functional role of LILRB4 in mediating the cross-talk between MM ad immune cells.
    CAR T-Cell Therapy • IO biomarker
    |
    IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
    |
    IL2RA expression • LILRB4 overexpression
    |
    bortezomib
    over1year
    Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer. (PubMed, Thorac Cancer)
    Together, signals through LILRB4 on tumor-infiltrating cells, including MDSCs, play an essential role in promoting tumor evasion and cancer progression, impacting the recurrence and poor prognosis of patients with resected NSCLC.
    Journal
    |
    CD33 (CD33 Molecule) • CD14 (CD14 Molecule) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
    |
    LILRB4 overexpression
    over1year
    A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS (EHA 2023)
    In combination therapy, 1 AML patient with high LILRB4 expression who was refractory to azacitidine and venetoclax based combination therapy achieved CR, ongoing at 7+ months. IO-202 is safe and well tolerated as monotherapy and in combination with AZA. Encouraging responses, including monotherapy activity, ongoing CR in an AML patient with high LILRB4 expression, and PR and Optimal Marrow Response in CMML patients, were observed. PD biomarker data supported proposed MOA.
    Clinical • P1 data
    |
    APOE (Apolipoprotein E) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4)
    |
    PGR expression • LILRB4 overexpression
    |
    Venclexta (venetoclax) • azacitidine • IO-202